NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free MYGN Stock Alerts $25.29 +0.68 (+2.76%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$24.48▼$25.5450-Day Range$17.98▼$25.4752-Week Range$13.82▼$25.95Volume598,558 shsAverage Volume951,983 shsMarket Capitalization$2.29 billionP/E RatioN/ADividend YieldN/APrice Target$25.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Myriad Genetics alerts: Email Address Myriad Genetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1.1% Upside$25.57 Price TargetShort InterestBearish6.57% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.32Based on 12 Articles This WeekInsider TradingSelling Shares$3.49 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.35) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.99 out of 5 starsMedical Sector624th out of 920 stocksDiagnostic Substances Industry7th out of 13 stocks 1.3 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMyriad Genetics has only been the subject of 3 research reports in the past 90 days.Read more about Myriad Genetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.57% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Myriad Genetics has recently increased by 8.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 1.8 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Myriad Genetics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for MYGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,490,730.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.35) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -8.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -8.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Myriad Genetics Stock (NASDAQ:MYGN)Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Read More MYGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYGN Stock News HeadlinesMay 17 at 6:02 AM | insidertrades.comPaul J. Diaz Sells 57,844 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) StockMay 16 at 1:38 PM | insidertrades.comLee Nisley Newcomer Sells 6,200 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) StockMay 17 at 5:06 AM | americanbankingnews.comPaul J. Diaz Sells 75,000 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) StockMay 16 at 4:05 PM | globenewswire.comNew Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerMay 16 at 3:22 AM | finance.yahoo.comInsider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)May 16 at 3:22 AM | finance.yahoo.comInsider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)May 15, 2024 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) PT Raised to $28.00 at Piper SandlerMay 12, 2024 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) Upgraded to Outperform at SVB LeerinkMay 11, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter ReportMay 11, 2024 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 9, 2024 | msn.comLeerink Partners Upgrades Myriad Genetics (MYGN)May 9, 2024 | finance.yahoo.comMyriad Genetics First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) Upgraded to Outperform at Leerink PartnrsMay 9, 2024 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) Shares Gap Up Following Earnings BeatMay 8, 2024 | marketwatch.comMyriad Genetics Shares Rise 15% After 1Q Revenue Beats EstimatesMay 8, 2024 | finance.yahoo.comMyriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comMyriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ...May 7, 2024 | investorplace.comMYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | uk.finance.yahoo.comMyriad Genetics Reports Q1 2024 Earnings: Revenue Growth Surpasses Estimates Amidst ChallengesMay 7, 2024 | markets.businessinsider.comMyriad Genetics Inc. Q1 Loss Decreases, beats estimatesMay 7, 2024 | msn.comMyriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.2M beats by $8.95MMay 7, 2024 | globenewswire.comMyriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDAMay 7, 2024 | finanznachrichten.deMyriad Genetics, Inc.: Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict BusinessMay 7, 2024 | globenewswire.comMyriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict BusinessMay 7, 2024 | finance.yahoo.comMyriad Genetics (NASDAQ:MYGN) shareholders have endured a 26% loss from investing in the stock five years agoSee More Headlines Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/19/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Stock Price Target$25.57 High Stock Price Target$35.00 Low Stock Price Target$14.00 Potential Upside/Downside+1.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,300,000.00 Net Margins-30.30% Pretax Margin-30.42% Return on Equity-6.77% Return on Assets-4.37% Debt Debt-to-Equity Ratio0.05 Current Ratio1.99 Quick Ratio1.82 Sales & Book Value Annual Sales$753.20 million Price / Sales3.04 Cash FlowN/A Price / Cash FlowN/A Book Value$8.40 per share Price / Book3.01Miscellaneous Outstanding Shares90,510,000Free Float88,607,000Market Cap$2.29 billion OptionableOptionable Beta1.96 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Paul J. Diaz (Age 62)CEO, President & Director Comp: $2.31MMr. Samraat S. Raha (Age 51)Chief Operating Officer Comp: $514.76kDr. Dale Muzzey Ph.D. (Age 44)Chief Scientific Officer Comp: $816.5kMr. Mark S. Verratti (Age 56)Chief Commercial Officer Comp: $915.81kMr. Scott J. Leffler (Age 49)Chief Financial Officer Ms. Natalie Munk (Age 43)Principal Accounting Officer Dr. Kevin Richard Haas Ph.D. (Age 38)Chief Technology Officer Comp: $580.36kMr. Matthew ScaloSenior Vice President of Investor RelationsMr. Glenn FarrellSenior VP & Chief Marketing OfficerMs. Shereen Solaiman (Age 51)Chief People Officer More ExecutivesKey CompetitorsCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLANeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELMeridian BioscienceNASDAQ:VIVOView All CompetitorsInsiders & InstitutionsComerica BankSold 2,855 shares on 5/17/2024Ownership: 0.088%Tidal Investments LLCBought 28,432 shares on 5/17/2024Ownership: 0.031%California State Teachers Retirement SystemBought 2,564 shares on 5/16/2024Ownership: 0.098%Paul J DiazSold 75,000 sharesTotal: $1.88 M ($25.07/share)Price T Rowe Associates Inc. MDBought 6,337 shares on 5/15/2024Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions MYGN Stock Analysis - Frequently Asked Questions Should I buy or sell Myriad Genetics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MYGN shares. View MYGN analyst ratings or view top-rated stocks. What is Myriad Genetics' stock price target for 2024? 8 brokerages have issued 1-year price objectives for Myriad Genetics' stock. Their MYGN share price targets range from $14.00 to $35.00. On average, they expect the company's stock price to reach $25.57 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts. How have MYGN shares performed in 2024? Myriad Genetics' stock was trading at $19.14 at the beginning of 2024. Since then, MYGN stock has increased by 32.1% and is now trading at $25.29. View the best growth stocks for 2024 here. When is Myriad Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our MYGN earnings forecast. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.09. The company earned $202.20 million during the quarter, compared to analysts' expectations of $193.51 million. Myriad Genetics had a negative net margin of 30.30% and a negative trailing twelve-month return on equity of 6.77%. The firm's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.28) earnings per share. What ETFs hold Myriad Genetics' stock? ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Inspire Small/Mid Cap ETF (ISMD).SPDR S&P 600 Small Cap ETF (SLY). What guidance has Myriad Genetics issued on next quarter's earnings? Myriad Genetics updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of 0.000-0.050 for the period, compared to the consensus earnings per share estimate of 0.020. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of $826.6 million. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS). Who are Myriad Genetics' major shareholders? Myriad Genetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.09%), Earnest Partners LLC (4.35%), Sei Investments Co. (2.53%), Principal Financial Group Inc. (0.52%), Mirae Asset Global Investments Co. Ltd. (0.37%) and Assenagon Asset Management S.A. (0.22%). Insiders that own company stock include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Lee Nisley Newcomer, Nicole Lambert, Paul J Diaz, Richard Bryan Riggsbee and S Louise Phanstiel. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Myriad Genetics have any subsidiaries? The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.Read More This page (NASDAQ:MYGN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.